C.R. Bard, Inc. (BCR) Hits New 12-Month High at $323.80
C.R. Bard, Inc. (NYSE:BCR)’s share price hit a new 52-week high during mid-day trading on Friday . The company traded as high as $323.80 and last traded at $323.79, with a volume of 240,875 shares. The stock had previously closed at $321.90.
A number of equities analysts have issued reports on BCR shares. Zacks Investment Research upgraded shares of C.R. Bard from a “hold” rating to a “buy” rating and set a $342.00 target price for the company in a research report on Thursday, May 11th. BidaskClub upgraded shares of C.R. Bard from a “buy” rating to a “strong-buy” rating in a research report on Saturday, July 8th. Finally, BMO Capital Markets restated a “hold” rating and set a $317.00 target price on shares of C.R. Bard in a research report on Tuesday, July 11th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, one has given a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $285.67.
The stock has a market capitalization of $23.53 billion, a price-to-earnings ratio of 42.52 and a beta of 0.60. The company has a 50 day moving average price of $320.16 and a 200 day moving average price of $294.45.
C.R. Bard (NYSE:BCR) last posted its quarterly earnings data on Thursday, July 27th. The medical instruments supplier reported $2.92 EPS for the quarter, beating analysts’ consensus estimates of $2.84 by $0.08. C.R. Bard had a net margin of 14.99% and a return on equity of 48.70%. The company had revenue of $979.70 million during the quarter, compared to analyst estimates of $976.53 million. During the same period in the prior year, the firm earned $2.54 earnings per share. The business’s quarterly revenue was up 5.2% on a year-over-year basis. Analysts predict that C.R. Bard, Inc. will post $11.84 EPS for the current year.
In other C.R. Bard news, insider John P. Groetelaars sold 23,687 shares of the company’s stock in a transaction dated Thursday, August 10th. The shares were sold at an average price of $318.73, for a total transaction of $7,549,757.51. Following the completion of the sale, the insider now directly owns 31,445 shares of the company’s stock, valued at $10,022,464.85. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 0.80% of the stock is currently owned by corporate insiders.
Hedge funds have recently bought and sold shares of the business. Mitsubishi UFJ Securities Holdings Co. Ltd. lifted its position in shares of C.R. Bard by 70.4% in the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 460 shares of the medical instruments supplier’s stock worth $145,000 after purchasing an additional 190 shares in the last quarter. ClariVest Asset Management LLC purchased a new stake in shares of C.R. Bard in the first quarter worth approximately $148,000. SRS Capital Advisors Inc. lifted its position in shares of C.R. Bard by 0.7% in the first quarter. SRS Capital Advisors Inc. now owns 598 shares of the medical instruments supplier’s stock worth $148,000 after purchasing an additional 4 shares in the last quarter. Parallel Advisors LLC lifted its position in shares of C.R. Bard by 283.8% in the first quarter. Parallel Advisors LLC now owns 499 shares of the medical instruments supplier’s stock worth $153,000 after purchasing an additional 369 shares in the last quarter. Finally, Captrust Financial Advisors purchased a new stake in shares of C.R. Bard in the second quarter worth approximately $192,000. 79.34% of the stock is owned by institutional investors.
C.R. Bard Company Profile
C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.